Print this page
-
Targeted Genomic Analysis of Human Cancers.
Protocol: 001209Principal Investigator:
- Shridar Ganesan
Applicable Disease Sites: Any Site -
A survey of pediatric and adolescent and young adult (AYA) cancer patients primary care providers (PCPs) regarding communication with the oncology team
Protocol: 002549Principal Investigator:
- Dawn Tortajada
Applicable Disease Sites: -
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies.
Protocol: 072014Applicable Disease Sites: Any Site
-
Project Every Child: A Registry, Eligibility Screening, Biology and Outcome Study.
Protocol: 111509Principal Investigator:
- Richard A Drachtman
Applicable Disease Sites: Any Site -
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors.
Protocol: 111702Principal Investigator:
- Nehal Parikh
Applicable Disease Sites: Any Site
Ovary
Prostate -
A Phase 2 Study of Inotuzumab Ozogamicin in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL).
Protocol: 111707Principal Investigator:
- Archana Sharma
Applicable Disease Sites: Lymphoid Leukemia -
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL).
Protocol: 111803Principal Investigator:
- Nehal Parikh
Applicable Disease Sites: Any Site -
A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumors.
Protocol: 111904Principal Investigator:
- Nehal Parikh
Applicable Disease Sites: Other Female Genital
Other Male Genital -
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL, Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy.
Protocol: 111911Principal Investigator:
- Marissa Botwinick
Applicable Disease Sites: Any Site -
Concordance of Self-reported Race and Ethnicity with Hospital Records Among Pediatric Patients.
Protocol: 112001Principal Investigator:
- Peter D. Cole
Applicable Disease Sites: Any Site -
Characterization of Brain Dysfunction During Development in Survivors of Childhood Acute Lymphoblastic Leukemia.
Protocol: 112002Principal Investigator:
- Peter D. Cole
Applicable Disease Sites: Leukemia, not otherwise specified -
A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations.
Protocol: 112008Principal Investigator:
- Marissa Botwinick
Applicable Disease Sites: Leukemia, not otherwise specified -
A Phase 2 Study of Blinatumomab in Combination with Nivolumab, a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged < 1 to < 31 Years Old with First Relapse.
Protocol: 112011Principal Investigator:
- Richard A Drachtman
Applicable Disease Sites: Any Site -
Novel Immune Checkpoint Expression on Circulating Tumor Cells of Sarcomas.
Protocol: 112103Principal Investigator:
- Scott A Moerdler
Applicable Disease Sites: Soft Tissue -
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT).
Protocol: 112106Principal Investigator:
- Scott A Moerdler
Applicable Disease Sites: Kidney -
A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma.
Protocol: 112201Principal Investigator:
- Scott A Moerdler
Applicable Disease Sites: Bones and Joints
Lung